Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Amgen
44 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
COVID-19
Iceland Provides a Picture of the Early Spread of COVID-19 in a Population with a Cohesive Public Health Response
PR-M05-20-NI-004
Facility
Amgen Selects Location for R&D Facility in ihe South San Francisco Biotechnology Hub
PR-M12-19-NI-014
Partner
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
PR-M11-19-NI-004
Strategic Collaboration
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
PR-M10-19-NI-048
Drug Pricing
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
PR-M10-19-NI-037
Positive Results
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients
PR-M09-19-NI-056
Investment
Rumors Suggest Amgen is Interested in Alexion
PAO-M00-19-NI-001
M&A
Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits
PR-M08-19-NI-083
KRAS Inhibitor
Amgen Reports Further Success with New KRAS Inhibitor
PAO-M08-19-NI-025
Collaboration
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
PR-M05-19-NI-014
Launch
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
PR-M04-19-NI-068
Drug Development
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
PR-M04-19-NI-054
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
PAO-M04-19-NI-015
Collaboration
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
PR-M03-19-NI-057
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
PR-M02-19-NI-059
Collaboration
Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
PR-M02-19-NI-052
Collaboration
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
PR-M02-19-NI-035
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
PR-M01-19-NI-079
Launch
GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification
PR-M01-19-NI-050
Medical Device
Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
PR-M01-19-NI-033
Biosimilar
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
PR-M01-19-NI-002
Clinical Trial Patient Populations
Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
PR-M12-18-NI-059
Financial Results
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
PR-M12-18-NI-036
Positive Opinion
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab)
PR-M11-18-NI-74
1
2
»
.svg)